Treatment for allergic rhinitis and chronic idiopathic urticaria: Focus on oral antihistamines

Annals of Pharmacotherapy

Volumn 39, Issue 12, 2005, Pages 2056-2064

  Morgan, Matthew M ^a   Khan, David A ^b   Nathan, Robert A ^c  

^a Allergy Asthma and Immunology of North Texas   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

Allergic rhinitis; Antihistamine(s); Chronic idiopathic urticaria

Indexed keywords

ANTIHISTAMINIC AGENT; ASTEMIZOLE; BROMPHENIRAMINE; CETIRIZINE; CHLORPHENIRAMINE; CYPROHEPTADINE; DESLORATADINE; DIPHENHYDRAMINE; FEXOFENADINE; HISTAMINE H1 RECEPTOR ANTAGONIST; HYDROXYZINE; KETOTIFEN; LORATADINE; MIZOLASTINE; MONOAMINE OXIDASE INHIBITOR; PLACEBO; PROMETHAZINE;

ADULT; ALLERGIC RHINITIS; ANOREXIA; BLOOD BRAIN BARRIER; CARDIOTOXICITY; CHILD; CHRONIC DISEASE; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; EPIGASTRIC PAIN; GASTROINTESTINAL SYMPTOM; HUMAN; NAUSEA; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SEDATION; SIDE EFFECT; TACHYCARDIA; URTICARIA; VOMITING; XEROSTOMIA;

CHRONIC DISEASE; COST-BENEFIT ANALYSIS; HISTAMINE ANTAGONISTS; HUMANS; RHINITIS, ALLERGIC, SEASONAL; URTICARIA;

EID: 28544435323     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E638     Document Type: Review

References (79)

1. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Lancet 1998;351:1225-32.
2. Wright AL, Holberg CJ, Martinez FD, Halonen M, Morgan W, Taussig LM. Epidemiology of physician-diagnosed allergic rhinitis in childhood. Pediatrics 1994;94:895-901.
3. Berger WE. Overview of allergic rhinitis. Ann Allergy Asthma Immunol 2003;90:7-12.
4. Greaves M. Chronic urticaria. J Allergy Clin Immunol 2000;105:664-72.
5. Cooper KD. Urticaria and angioedema: diagnosis and evaluation. J Am Acad Dermatol 1991;25:166-76.
6. Marshall PS, O'Hara C, Steinberg P. Effects of seasonal allergic rhinitis on fatigue levels and mood. Psychosom Med 2002;64:684-91.
7. Meltzer EO. Quality of life in adults and children with allergic rhinitis. J Allergy Clin Immunol 2001;108(1 suppl):S45-53.
8. Borish L. Allergic rhinitis: systemic inflammation and implications for management. J Allergy Clin Immunol 2003;112:1021-31.
9. O'Donnell BF, Lawlor F, Simpson J, Morgan M, Greaves MW. The impact of chronic urticaria on the quality of life. Br J Dermatol 1997;136:197-201.
10. Poon E, Seed PT, Greaves MW, Kobza-Black A. The extent and nature of disability in different urticarial conditions. Br J Dermatol 1999;140:667-71.
11. White MV. The role of histamine in allergic diseases. J Allergy Clin Immunol 1990;86:599-605.
12. Stander S, Steinhoff M, Schmelz M, Weisshaar E, Metze D, Luger T. Neurophysiology of pruritus: cutaneous elicitation of itch. Arch Dermatol 2003;139:1463-70.
13. Howarth PH, Salagean M, Dokic D. Allergic rhinitis: not purely a histamine-related disease. Allergy 2000;55(suppl 64):7-16.
14. Greaves MW. Chronic idiopathic urticaria. Curr Opin Allergy Clin Immunol 2003;3:363-8.
15. Bousquet J, van Cauwenberge P, Khaltaev N, Aria Workshop Group, World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108(suppl 5):S147-334.
16. Casale TB, Blaiss MS, Gelfand E, Gilmore T, Harvey PD, Hindmarch I, et al., Antihistamine Impairment Roundtable. First do no harm: managing antihistamine impairment in patients with allergic rhinitis. J Allergy Clin Immunol 2003;111:S835-42.
17. Zareba W, Moss AJ, Rosero SZ, Hajj-Ali R, Konecki J, Andrews M. Electrocardiographic findings in patients with diphenhydramine overdose. Am J Cardiol 1997;80:1168-73.
18. Jumbelic MI, Hanzlick R, Cohle S. Alkylamine antihistamine toxicity and review of pediatric registry of the National Association of Medical Examiners. Am J Forensic Med Pathol 1997;18:65-9.
19. Goetz CM, Lopez G, Dean BS, Krenzelok EP. Accidental childhood death from diphenhydramine overdosage. Am J Emerg Med 1990;8:321-2.
20. Le Blaye I, Donatini B, Hall M, Krupp P. Acute ketotifen overdosage. A review of present clinical experience. Drug Saf 1992;7:387-92.
21. Qidwai JC, Watson GS, Weiler JM. Sedation, cognition, and antihistamines. Curr Allergy Asthma Rep 2002;2:216-22.
22. Craft TM. Torsade de pointes after astemizole overdose. Br Med J (Clin Res Ed) 1986;292:660.
23. Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J, Cantilena LR Jr. Torsades de pointes occurring in association with terfenadine use. JAMA 1990;264:2788-90.
24. Hindmarch I, Shamsi Z. Antihistamines: models to assess sedative properties, assessment of sedation, safety and other side-effects. Clin Exp Allergy 1999;29(suppl 3):133-42.
25. Shamsi Z, Hindmarch I. Sedation and antihistamines: a review of inter-drug differences using proportional impairment ratios. Hum Psychopharmacol 2000;15(S1):S3-30.
26. 1 antagonists measured by positron emission tomography. Br J Pharmacol 1995;116:1649-55.
27. 1 receptors in human brain. Life Sci 2002;72:409-14.
28. Pratt C, Brown AM, Rampe D, Mason J, Russell T, Reynolds R, et al. Cardiovascular safety of fexofenadine HCl. Clin Exp Allergy 1999;29(suppl 3):212-6.
29. Dockhorn R, Bergner A, Cornell JT, Falliers CJ, Grabiec SV, Weiler JM, et al. Safety and efficacy of loratadine (SCH-29851): a new non-sedating antihistamine in seasonal allergic rhinitis. Ann Allergy 1987;58:407-11.
30. Irander K, Odkvist LM, Ohlander B. Treatment of hay fever with loratadine-a new non-sedating antihistamine. Allergy 1990;45:86-91.
31. Falliers C, Brandon ML, Buchman E, Cornell JT, Dockhorn R, Leese PT, et al. Double-blind comparison of cetirizine and placebo in the treatment of seasonal rhinitis. Ann Allergy 1991;66:257-62.
32. Lockey RF, Widlitz MD, Mitchell DQ, Lumry W, Dockhorn R, Woehler T, et al. Comparative study of cetirizine and terfenadine versus placebo in the symptomatic management of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1996;76:448-54.
33. Simons FE, Prenner BM, Finn A Jr, Desloratadine Study Group. Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis. J Allergy Clin Immunol 2003;111:617-22.
34. Salmun LM, Lorber R. 24-hour efficacy of once-daily desloratadine therapy in patients with seasonal allergic rhinitis [ISRCTN32042139]. BMC Fam Pract 2002;3:14.
35. Bernstein DI, Schoenwetter WF, Nathan RA, Storms W, Ahlbrandt R, Mason J. Efficacy and safety of fexofenadine hydrochloride for treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1997;79:443-8.
36. 1-receptor antagonist in the treatment of fall allergies. Allergy Asthma Proc 1998;19:135-41.
37. Day JH, Briscoe MP, Clark RH, Ellis AK, Gervais P. Onset of action and efficacy of terfenadine, astemizole, cetirizine, and loratadine for the relief of symptoms of allergic rhinitis. Ann Allergy Asthma Immunol 1997;79:163-72.
38. Day JH, Briscoe M, Widlitz MD. Cetirizine, loratadine, or placebo in subjects with seasonal allergic rhinitis: effects after controlled ragweed pollen challenge in an environmental exposure unit. J Allergy Clin Immunol 1998;101:638-45.
39. Day JH, Briscoe M, Rafeiro E, Chapman D, Kramer B. Comparative onset of action and symptom relief with cetirizine, loratadine, or placebo on an environmental exposure unit in subjects with seasonal allergic rhinitis: confirmation of a test system. Ann Allergy Asthma Immunol 2001;87:474-81.
40. Meltzer EO, Weiler JM, Widlitz MD. Comparative outdoor study of the efficacy, onset and duration of action, and safety of cetirizine, loratadine, and placebo for seasonal allergic rhinitis. J Allergy Clin Immunol 1996;97:617-26.
41. Herman D, Arnaud A, Dry J, Latil G, Pauli G, Perrin-Fayolle M, et al. [Clinical effectiveness and tolerance of loratadine versus cetirizine in the treatment of seasonal allergic rhinitis] French. Allerg Immunol (Paris) 1992;244:270-4.
42. Nunes C, Ladeira S. Double-blind study of cetirizine and loratadine versus placebo in patients with allergic rhinitis. J Investig Allergol Clin Immunol 2000;10:20-3.
43. van Cauwenberge P, Juniper EF. Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis. Clin Exp Allergy 2000;30:891-9.
44. Prenner BM, Capano D, Harris AG. Efficacy and tolerability of loratadine versus fexofenadine in the treatment of seasonal allergic rhinitis: a double-blind comparison with crossover treatment of nonresponders. Clin Ther 2000;22:760-9.
45. Wilson AM, Haggart K, Sims EJ, Lipworth BJ. Effects of fexofenadine and desloratadine on subjective and objective measures of nasal congestion in seasonal allergic rhinitis. Clin Exp Allergy 2002;32:1504-9.
46. Howarth PH, Stern MA, Roi L, Reynolds R, Bousquet J. Double-blind, placebo-controlled study comparing the efficacy and safety of fexofena-dine hydrochloride (120 and 180 mg once-daily) and cetirizine in seasonal allergic rhinitis. J Allergy Clin Immunol 1999;104:927-33.
47. Hampel F, Ratner P, Mansfield L, Meeves S, Liao Y, Georges G. Fexofenadine hydrochloride, 180 mg, exhibits equivalent efficacy to cetirizine, 10 mg, with less drowsiness in patients with moderate-to-severe seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2003;91:354-61.
48. Horak F, Stubner P, Zieglmayer R, Kavina A, De Vos C, Burtin B, et al. Controlled comparison of the efficacy and safety of cetirizine 10 mg o.d. and fexofenadine 120 mg o.d. in reducing symptoms of seasonal allergic rhinitis. Int Arch Allergy Immunol 2001;125:73-9.
49. Day JH, Briscoe MP, Rafeiro E, Hewlett D Jr, Chapman D, Kramer B. Randomized double-blind comparison of cetirizine and fexofenadine after pollen challenge in the environmental exposure unit: duration of effect in subjects with seasonal allergic rhinitis. Allergy Asthma Proc 2004;25:59-68.
50. Graft DF, Bernstein DI, Goldsobel A, Meltzer EO, Portnoy J, Long J. Safety of fexofenadine in children treated for seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2001;87:22-6.
51. Wahn U, Meltzer EO, Finn AF Jr, Kowalski ML, Decosta P, Hedlin G, et al. Fexofenadine is efficacious and safe in children (aged 6-11 years) with seasonal allergic rhinitis. J Allergy Clin Immunol 2003;111:763-9.
52. Lutsky BN, Klose P, Melon J, Menardo JL, Molkhou P, Ronchetti R, et al. A comparative study of the efficacy and safety of loratadine syrup and terfenadine suspension in the treatment of 3- to 6-year-old children with seasonal allergic rhinitis. Clin Ther 1993;15:855-65.
53. Allegra L, Paupe J, Wieseman HG, Baelde Y. Cetirizine for seasonal allergic rhinitis in children aged 2-6 years. A double-blind comparison with placebo. Pediatr Allergy Immunol 1993;4:157-61.
54. Pearlman DS, Lumry WR, Winder JA, Noonan MJ. Once-daily cetirizine effective in the treatment of seasonal allergic rhinitis in children aged 6 to 11 years: a randomized, double-blind, placebo-controlled study. Clin Pediatr 1997;36:209-15.
55. 1-receptor antagonist cetirizine in very young children with atopic dermatitis. ETAC Study Group. Early Treatment of the Atopic Child. J Allergy Clin Immunol 1999;104:433-40.
56. Rossi GA, Tosca MA, Passalacqua G, Bianchi B, Le Grazie C, Canonica GW. Evidence of desloratadine syrup efficacy and tolerability in children with pollen-induced allergic rhinitis. Allergy 2005;60:416-7.
57. Bloom M, Staudinger H, Herron J. Safety of desloratadine syrup in children. Curr Med Res Opin 2004;20:1959-65.
58. Sienra-Monge JJ, Gazca-Aguilar A, Del Rio-Navarro B. Double-blind comparison of cetirizine and loratadine in children ages 2 to 6 years with perennial allergic rhinitis. Am J Ther 1999;6:149-55.
59. Black AK, Greaves MW. Antihistamines in urticaria and angioedema. Clin Allergy Immunol 2002;17:249-86.
60. Monroe EW. Relative efficacy and safety of loratadine, hydroxyzine, and placebo in chronic idiopathic urticaria and atopic dermatitis. Clin Ther 1992;14:17-21.
61. Leynadier F, Duarte-Risselin C, Murrieta M. Comparative therapeutic effect and safety of mizolastine and loratadine in chronic idiopathic urticaria. URTTLOR study group. Eur J Dermatol 2000;10:205-11.
62. Breneman D, Bronsky EA, Bruce S, Kalivas JT, Klein GL, Roth HL, et al. Cetirizine and astemizole therapy for chronic idiopathic urticaria: a double-blind, placebo-controlled, comparative trial. J Am Acad Dermatol 1995;33:192-8.
63. La Rosa M, Leonardi S, Marchese G, Corrias A, Barberio G, Oggiano N, et al. Double-blind multicenter study on the efficacy and tolerability of cetirizine compared with oxatomide in chronic idiopathic urticaria in preschool children. Ann Allergy Asthma Immunol 2001;87:48-53.
64. Ring J, Hein R, Gauger A, Bronsky E, Miller B. Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Int J Dermatol 2001;40:72-6.
65. Monroe E, Finn A, Patel P, Guerrero R, Ratner P, Bernstein D, Desloratadine Urticaria Study Group. Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial. J Am Acad Dermatol 2003;48:535-41.
66. Paul E, Berth-Jones J, Ortonne J-P, Stern M. Fexofenadine hydrochloride in the treatment of chronic idiopathic urticaria: a placebo-controlled, parallel-group, dose-ranging study. J Dermatolog Treat 1998;9:143-9.
67. Finn AF Jr, Kaplan AP, Fretwell R, Qu R, Long J. A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria. J Allergy Clin Immunol 1999;104:1071-8.
68. Handa S, Dogra S, Kumar B. Comparative efficacy of cetirizine and fexofenadine in the treatment of chronic idiopathic urticaria. J Dermatolog Treat 2004;15:55-7.
69. Ramaekers J, Vermeeren A. All antihistamines cross blood-brain barrier (letter). BMJ 2000;321:572.
70. Philpot EE. Safety of second generation antihistamines. Allergy Asthma Proc 2000;21:15-20.
71. Product information (UK). Clarinex (desloratadine). Kenilworth, NJ: Schering Corporation, August 2004.
72. Nolen TM. Sedative effects of antihistamines: safety, performance, learning, and quality of life. Clin Ther 1997;19:39-55.
73. Mattila MJ, Paakkari I. Variations among non-sedating antihistamines: are there real differences? Eur J Clin Pharmacol 1999;55:85-93.
74. Harvey RP, Wegs J, Schocket AL. A controlled trial of therapy in chronic urticaria. J Allergy Clin Immunol 1981;68:262-6.
75. 2 antihistamine therapy in chronic urticaria. Arch Dermatol 1981;117:404-7.
76. Malone DC, Lawson KA, Smith DH, Arrighi HM, Battista C. A cost of illness study of allergic rhinitis in the United States. J Allergy Clin Immunol 1997;99:22-7.
77. Sullivan PW, Follin SL, Nichol MB. Transitioning the second-generation antihistamines to over-the-counter status: a cost-effectiveness analysis. Med Care 2003;41:1382-95.
78. Fireman P. Treatment of allergic rhinitis: effect on occupation productivity and work force costs. Allergy Asthma Proc 1997;18:63-7.
79. 1-antihistamines. Clin Allergy Immunol 2002;17:319-36.